Financial Performance - Revenue for Q2 2024 was $13,206,717, representing a 6.82% increase from $12,363,429 in Q2 2023[174] - Revenue for the first half of 2024 was $27,791,190, an increase of 12.45% compared to $24,713,206 in the same period of 2023[174] - The net loss for Q2 2024 was $2,590,711, compared to a net loss of $981,530 in Q2 2023[174] - The net loss for the first half of 2024 was $4,457,401, up from a net loss of $1,441,393 in the same period of 2023[174] - The Company had a net loss of $4,457,401 for the six months ended June 30, 2024, with total revenue of $27,791,190[189] Revenue Drivers - The increase in revenue is attributed to the wholesale revenue stream and the contribution from the acquisition of Cana[174] - The company completed the acquisition of Cana for €800,000 and 46,377 shares of common stock valued at $800,000[170] - The acquisition of Bikas is projected to increase annual revenue by more than $10 million and enhance gross margins[172] - The company acquired Cloudscreen, an AI-powered platform for drug repurposing, for a total price of $637,080[173] Cost and Expenses - The Company reported a cost of goods sold of $12,349,469 for the three months ended June 30, 2024, an increase of 8.96% compared to $11,416,595 for the same period in 2023[175] - Gross profit decreased by 18.97% to $767,248 for the three months ended June 30, 2024, down from $946,834 in 2023, primarily due to decreased sales in high-margin revenue streams[177] - Operating expenses for the three months ended June 30, 2024, were $2,502,026, a decrease of 7.21% compared to $2,576,465 in 2023, with general and administrative costs decreasing by 30.48%[178] Working Capital and Investments - As of June 30, 2024, the Company had working capital of $8,593,711, down from $12,285,310 as of December 31, 2023[184] - The company intends to strengthen working capital and invest in R&D, sales, and marketing, although actual expenditures may differ from planned allocations due to industry uncertainties[206] - The Company raised $649,039 from the sale of 901,488 shares of common stock during the six months ended June 30, 2024[187] Strategic Initiatives - The Company plans to expand its product portfolio to 150 SKUs by the end of 2023, focusing on various customer needs and advanced formulations[193] - The Company intends to enhance its geographic expansion in the EU, Asia, USA, and Canada through exclusive distributors and acquisitions of nutraceutical companies[193] - Management plans to vertically integrate the supply chain distribution network and evaluate acquisition targets to expand distribution[191] - The company plans to actively pursue acquisitions to enhance its distribution network, focusing on discounted assets through business combinations or joint ventures[200] - The company aims to expand its R&D division to develop new patented pharmaceuticals and innovative nutraceutical products, fostering organic growth through enhanced marketing efforts[200] Market Opportunities - The pharmaceutical sector presents significant growth potential in the European market, contingent on aligning services, pricing, and quality with customer requirements[198] - The company is experiencing strong demand for its branded nutraceuticals, with positive feedback from major health events[202] - Sky Premium Life products are being sold in over 1,600 stores across 18 countries, generating approximately $1 billion in annual revenue for Holland & Barrett, a key retailer[203] - The company is launching Mediterranation, a premium food supplements brand, utilizing organic herbs and plant extracts from the Mediterranean region[204] - The global baby food market is valued at $102.90 billion, presenting an opportunity for the relaunch of the Bio-Bebe brand[205] - The global antiseptic and disinfectant market is worth $29 billion, with the company positioned to capitalize on this through the expansion of the C-Sept brand[205] Internal Controls and Governance - The company is addressing material weaknesses in its internal controls and plans to complete remediation by December 31, 2024[217] - The internal control structure currently lacks proper segregation of duties and multiple levels of review and oversight[218] - A new financial reporting application is being assessed to enhance IT General Controls and improve financial reporting efficiency[219] - The Audit Committee is responsible for overseeing the financial reporting and accounting processes, and it meets at least four times a year[223] - There have been no changes in internal control over financial reporting that materially affect the Company[220] - The Audit Committee maintains direct communication with independent auditors and is authorized to investigate any matters brought to its attention[222] - The Company is updating its organizational chart to better allocate roles and responsibilities among personnel[218] - Management reviews bank reconciliations and discrepancies between the general ledger and bank statements to ensure timely reporting[219] - The Audit Committee includes three independent directors and is chaired by Dr. Anastasios Aslidis[221] - The Company plans to enhance its IT risk management and control design to address existing weaknesses[217]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Nevada 27-0611758 (State or other jurisdiction of Company or organization) (I.R.S. Employer Identification No.) FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________ to __________ Commission file number: 000-54436 COSMOS HEALTH INC. (E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________ to __________ Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of Company or organization) ...

Greg Siokas, CEO of Cosmos Health, said the following about the agreement with Pharmalink. COSM stock is up 64.7% as of Friday morning. However, the stock was down 50.4% year-to-date when markets closed yesterday. On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam a ...

The healthcare industry has experienced unprecedented growth in recent years due to the global pandemic. However, as COVID-19 began to ease, the immense growth of the healthcare industry is expected to slow down. Additionally, because many healthcare companies rely on trials that need FDA approval, predicting their individual healthcare company’s performance is difficult. These companies experience massive declines in share price when their trials fail. Combining relatively slowed growth with risk factors, ...

Table of Contents The Company had interest expense related to notes payable of $151,274 and $529,782 versus $517,660 and $1,772,750 and non-cash interest expense related to the amortization of debt discount of $0 and $0 versus $295,846 and $772,180 for the three and nine months ended September 30, 2023 and 2022, respectively. The decrease Finally, the Company has recorded a bargain purchase gain of $1,633,842 versus $0 for the nine months ended September 30, 2023 and 2022, respectively. The bargain purchase ...

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 For the transition period from ___________ to ___________ | --- | |-------| | | | | | | | | | | | | | | | | | | | | 60604 (ZipCode) TitleofEachClass ☒ TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT Commission file number: 000-54436 COSMOS HEALTH INC. (Exact name of registra ...

Supply chain disruption is a growing concern for the European pharmaceutical industry as it increasingly looks to cut costs by relying on 'emerging markets', where standards can be lower in terms of compliance, ethics and health and safety. Distribution and Trade Agreements On November 25, 2021 SkyPharm SA signed a trade agreement with a wholesaler which operates in the storage, distribution, trading and promotion of pharmaceutical products) henceforward referred as "Distributor C". Based on the agreement D ...

☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-54436 Registrant's telephone number: (312) 536-3102 Securities registered under Section 12(g) of the Exchange Act: Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ___________ to ___________ Commission file number: 000-54436 COSMOS HOLDINGS INC. (Exact name of registrant as specified in its charter) Nevada 27-0611758 (State or other jurisdiction of incorpora ...